Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CHI, FEA

March Of Dimes Awards Grants To Evaluate Impact Of COVID-19 On Maternal And Infant Health


ARLINGTON, VA, Nov. 19, 2020 /PRNewswire/ -- March of Dimes, the nation's leader in the fight for the health of all moms and babies, has awarded research grants to Massachusetts General Hospital and the University of Pennsylvania as part of its work to address the health threats facing pregnant women and babies during the COVID-19 pandemic. The research teams will improve public understanding of COVID-19's potential impact on altering the placenta that could trigger adverse pregnancy outcomes and disruption of the protective immune responses between moms and babies. These grants are made possible by donor support of the March of Dimes COVID-19 Intervention and Support Fund, which has raised more than $1 million to address the urgent need for research, advocacy and education to protect mom and babies from COVID-19 and its unknown future effects.

"We're proud to support researchers with funding to advance our understanding of COVID-19 and its current and future impact on moms and babies," said Dr. Rahul Gupta, Chief Medical and Health Officer, Senior Vice President and Interim Chief Scientific Officer at March of Dimes. "We still have a lot to learn about this virus and its impact on maternal and infant health. Prioritizing critical research like this is vital to building knowledge that will protect our nation's moms and babies during this public health emergency."  

The following teams will each receive a $125,000 grant from March of Dimes for the following research: 

"We look forward to increasing knowledge about the transfer of antibodies from mother to baby in COVID-19, both via the placenta and the breast," said Dr. Edlow. "Understanding neonatal protection and vulnerability will be critical to informing vaccine strategies for pregnant patients and providing mothers with evidence-based data regarding breastfeeding. Our multidisciplinary team, including Dr. Kathryn Gray and Dr. Mandy Belfort at Brigham and Women's Hospital and Dr. Galit Alter at the Ragon Institute of MIT, will work together to advance knowledge as rapidly as possible."

"We are grateful to the March of Dimes for the opportunity to study extracellular vesicles circulating in pregnant women with COVID-19," said Drs. Simmons and Parry. "These extracellular vesicles have been implicated in organ injury in non-pregnant adults with COVID-19 and may induce placental pathological changes that have been observed in COVID-19 pregnancies."

The Mom and Baby COVID-19 Intervention and Support Fund

Through the fund, March of Dimes will continue to secure donations to support critical research to enhance understanding of COVID-19's impact on maternal and infant health. This fund also enables March of Dimes to advocate on behalf of moms and babies during the pandemic, educate the public about precautionary measures, and provide critical items like face masks, blood pressure cuffs and breast pumps. As part of its advocacy work, March of Dimes is calling on the government to close the research gap in vaccine development and include pregnant and lactating women in COVID-19 clinical trials. For more information about the fund and how you can make a donation to support moms and babies throughout the pandemic, visit marchofdimes.org/covid19fund.

About March of Dimes

March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every baby can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we empower every mom and every family.

Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.

SOURCE March of Dimes


These press releases may also interest you

19 mai 2024
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

19 mai 2024
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

19 mai 2024
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: